Esperion Preps Nexletol/Nexlizet To Be ‘Clear Next Step’ After Statins
Outcomes Data Presented At ACC
Executive Summary
The company plans to ramp up its commercial infrastructure later this year, ahead of a labeling update based on positive cardiovascular outcomes trial data.